Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 4
2022 3
2023 6
2024 5
2025 9
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. Retraction in: N Engl J Med. 2026 Jun 29. doi: 10.1056/NEJMe2608684. PMID: 33596356 Retracted. Clinical Trial.
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associat …
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibo …
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.
Cortazar FB, Niles JL, Jayne DRW, Merkel PA, Bruchfeld A, Yue H, Schall TJ, Bekker P; ADVOCATE Study Group. Cortazar FB, et al. Kidney Int Rep. 2023 Feb 3;8(4):860-870. doi: 10.1016/j.ekir.2023.01.039. eCollection 2023 Apr. Kidney Int Rep. 2023. PMID: 37069984 Free PMC article.
INTRODUCTION: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (e …
INTRODUCTION: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic auto …
Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage.
Chalkia A, Flossmann O, Jones R, Nair JR, Simpson T, Smith R, Willcocks L, Jayne D. Chalkia A, et al. Nephrol Dial Transplant. 2024 Aug 30;39(9):1473-1482. doi: 10.1093/ndt/gfae020. Nephrol Dial Transplant. 2024. PMID: 38268434 Free PMC article.
BACKGROUND: Pulmonary haemorrhage with hypoxia caused by anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a high early mortality. Avacopan, an oral C5a receptor antagonist, is an approved treatment for AAV, but patients with …
BACKGROUND: Pulmonary haemorrhage with hypoxia caused by anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis …
Avacopan for ANCA-associated vasculitis: Beyond the 52-week treatment course.
Eisinger E, Geara AS, Chang B, Reddivari P, Ford J, Gewurz-Singer O, Geetha D. Eisinger E, et al. Clin Nephrol. 2025 Nov;104(5):338-342. doi: 10.5414/CN111775. Clin Nephrol. 2025. PMID: 40736179
The landmark ADVOCATE trial, which lead to the approval of Avacopan (AVP) as adjunctive treatment of ANCA-associated vasculitis (AAV), treated patients with AVP for 52 weeks. ...
The landmark ADVOCATE trial, which lead to the approval of Avacopan (AVP) as adjunctive treatment of ANCA-associated …
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.
Geetha D, Pagnoux C, Sattui SE, Merkel PA, Weiner M, Draibe J, Faguer S, Bray S, Gurlin RE, Balcells-Oliver M, Bruchfeld A, Jayne DR; ADVOCATE Study Group. Geetha D, et al. Rheumatology (Oxford). 2025 Jun 1;64(6):3863-3871. doi: 10.1093/rheumatology/keaf122. Rheumatology (Oxford). 2025. PMID: 40037556 Free PMC article. Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of avacopan in patients aged 65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cycl …
OBJECTIVES: To evaluate the efficacy and safety of avacopan in patients aged 65 years with granulomatosis with polyangiitis (GPA) or …
Treatment With Avacopan in ANCA-Associated Vasculitis With Kidney Involvement.
Geetha D, Cortazar FB, Bruchfeld A, Kronbichler A, Karras A, Nakhoul GN, Merkel PA, Bray S, Bozeman AM, Jayne DRW; ADVOCATE Study Group. Geetha D, et al. Kidney Int Rep. 2025 Jun 2;10(8):2751-2765. doi: 10.1016/j.ekir.2025.05.041. eCollection 2025 Aug. Kidney Int Rep. 2025. PMID: 40814647 Free PMC article.
This post hoc analysis evaluated the effect of avacopan in a subgroup of patients with GPA or MPA and kidney involvement at baseline from the ADVOCATE trial. ...Relapse rate after remission was lower in the avacopan than in the prednisone taper group (9.4% vs …
This post hoc analysis evaluated the effect of avacopan in a subgroup of patients with GPA or MPA and kidney involvement at baseline …
Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
Geetha D, Dua A, Yue H, Springer J, Salvarani C, Jayne D, Merkel P; ADVOCATE Study Group. Geetha D, et al. Ann Rheum Dis. 2024 Jan 11;83(2):223-232. doi: 10.1136/ard-2023-224816. Ann Rheum Dis. 2024. PMID: 37979959 Free PMC article. Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of avacopan in the subgroup of patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis receiving background induction therapy with rituximab in the phase 3 ADVOCATE …
OBJECTIVES: To evaluate the efficacy and safety of avacopan in the subgroup of patients with antineutrophil cytoplasmic …
Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C, Kopelman H, Zaino M, Feldman SR. Alihosseini C, et al. Ann Pharmacother. 2023 Dec;57(12):1449-1454. doi: 10.1177/10600280231161592. Epub 2023 Mar 28. Ann Pharmacother. 2023. PMID: 36975183
OBJECTIVE: To review the safety and efficacy of avacopan for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ...CONCLUSIONS: Avacopan used in isolation or combination is safe and effective for ANCA-asso …
OBJECTIVE: To review the safety and efficacy of avacopan for the treatment of anti-neutrophil cytoplasmic antibody (ANCA …
Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Zonozi R, Aqeel F, Le D, Cortazar FB, Thaker J, Zabala Ramirez MJ, Sattui Cortes SE, Attieh RM, Chung M, Bulbin DH, Shaikh A, Guaman K, Ford J, Diffie C, Gewurz-Singer O, Sauvage G, Jeyabalan A, Geara A, Ayoub I, Bomback A, Khoury LL, George JC, Jhaveri KD, Derebail VK, Niles JL, Geetha D. Zonozi R, et al. Kidney Int Rep. 2024 Mar 26;9(6):1783-1791. doi: 10.1016/j.ekir.2024.03.022. eCollection 2024 Jun. Kidney Int Rep. 2024. PMID: 38899183 Free PMC article.
INTRODUCTION: Postmarketing data on outcomes of avacopan use in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) are lacking. ...CONCLUSION: A high rate of remission and an acceptable safety profile were observed with t …
INTRODUCTION: Postmarketing data on outcomes of avacopan use in antineutrophil cytoplasmic autoantibody (ANCA)-a …
32 results